A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2025
This article has no abstract
Epistemonikos ID: 3f8fb8f2bc40a337994a7b2c8eddc3add0cdd52a
First added on: Jan 17, 2026